Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Efient

Eli Lilly HQ

Lilly inks $690m deal with Hanmi for autoimmune drug

Lilly to pay $50m upfront for rights to HM71224

- PMLiVE

GSK and Lilly invest in $100m global Dementia Discovery Fund

Fund announced at WHO conference by UK health secretary Jeremy Hunt

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

Eli Lilly HQ

German court overturns patent on Lilly blockbuster Alimta

Verdict means Actavis can launch generic after December

National Institute for Health and Care Excellence NICE logo

Patients should have a say in their medication, claims NICE

Also states health practitioners should be able to share information

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links